Current tools for modern staging of urothelial tumours
Poster Session 32
-
Location:Room Stockholm (Hall B2, level 0)
-
Chairs:
-
Aims and objectives of this session Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous entity including different substages of superficial tumours with specific evolution and prognosis. The risks of recurrence and progression in NMIBC are largely influenced by well-known risk factors, such as stage, grade, multifocality, tumour size and concomitant CIS Thus, risk tables and scoring systems have been developed by the EORTC group to adapt the treatment to the aggressiveness of the disease. The current session is dedicated to current staging of urothelial tumours.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany
Institutes: 1Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Urology, Dresden Johannstadt Nord, Germany, 2Biotype Diagnostic GmbH, Dept. of Research and Development, Dresden, Germany, 3Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Pathology, Dresden Johannstadt Nord, Germany
Institutes: 1Lund University, Dept. of Translational Medicine, Malmö, Sweden, 2Lund University, Dept. of Translational Medicine, Helsingborg, Sweden, 3Dept. of Clinical Sciences Lund University, Dept. of Oncology, Lund, Sweden
Institutes: 1Uri, Irccs San Raffaele Scientific Institute, Dept. of Oncology and Urology, Milan, Italy, 2Uri, Irccs San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, 3Uri, Irccs San Raffaele Scientific Institute, Dept. of Urology and Experimental Oncology, Milan, Italy, 4Medical University of Vienna, Dept. of Urology, Vienna, Austria, 5Università Degli Studi Di Palermo, Dept. of Discipline and Surgical Oncology, Palermo, Italy, 6Magna Græcia University of Catanzaro, Dept. of Urology and Doctorate Research Program, Catanzaro, Italy
Institutes: 1Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, 2Medical University Innsbruck, Dept. of Radiology, Innsbruck, Austria, 3Medical University Innsbruck, Dept. of Medical Statistics, Informatics and Health Economics, Innsbruck, Austria, 4Medical University Innsbruck, Dept. of Nuclear Medicine, Innsbruck, Austria
Institutes: 1Frimley Park Hospital, Dept. of Urology, Henley on Thames, United Kingdom, 2University of Birmingham, The Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, 3Frimley Park Hospital, Dept. of Radiology, Frimley, United Kingdom, 4Frimley Park Hospital, Dept. of Urology, Frimley, United Kingdom
Institutes: 1Sozialmedizinisches Zentrum Ost – Donauspital, Dept. of Urology, Vienna, Austria, 2Medical University of Vienna, Dept. of Histopathology, Vienna, Austria, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4Wilhelminenspital, Dept. of Urology, Vienna, Austria, 5Medical University of Vienna, Dept. of Radiology, Vienna, Austria
Institutes: 1Universitat Autònoma de Barcelona – Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 2Hospital De Sant Pau I La Santa Creu, Dept. of Oncology, Barcelona, Spain, 3Hospital De Sant Pau I La Santa Creu, Dept. of Nuclear Medicine, Barcelona, Spain
Institutes: 1Sozialmedizinisches Zentrum Ost – Donauspital, Dept. of Urology, Vienna, Austria, 2Wilhelminenspital, Dept. of Urology, Vienna, Austria, 3Sozialmedizinisches Zentrum Ost-Donauspital, Dept. of Urology, Vienna, Austria, 4Medical University of Vienna, Dept. of Histopathology, Vienna, Austria, 5Medical University of Vienna, Dept. of Urology, Vienna, Austria, 6Medical University of Vienna, Dept. of Radiology, Vienna, Austria